BRNS Barinthus Biotherapeutics plc
Healthcare$0.69-1.98%ClosedMarket Cap: $28.1M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
0.42
P/S
0.00
EV/EBITDA
0.57
DCF Value
$1.48
FCF Yield
-129.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-63.9%
ROA
-56.7%
ROIC
-68.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-9.1M | $-5.5M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-9.4M | $-11.1M | $— | — |
| FY null | $0.00 | -Infinity% | $-54.2M | $-66.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-15.1M | $-14.6M | $— | — |
| Q2 null | $0.00 | NaN% | $-23.3M | $-21.1M | $— | — |
| Q1 null | $0.00 | NaN% | $-20.6M | $-19.6M | $— | — |
| Q4 null | $0.00 | NaN% | $-23.4M | $-20.5M | $— | — |
| FY null | $15.0M | 100.0% | $-68.0M | $-61.1M | $— | — |
| Q3 null | $15.0M | 100.0% | $-9.4M | $-8.1M | $— | — |
| Q2 null | $0.00 | NaN% | $-18.3M | $-16.9M | $— | — |
| Q1 null | $0.00 | NaN% | $-16.9M | $-15.5M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-20.0M | $-17.3M | $-0.45 | — |